Veeda Clinical Research, one of the leading contract research organisations (CRO) in the country with presence in Europe and the US, is set to expand its operations further by acquiring two overseas.
United Kingdom of Great Britain & N. Ireland (Press Release) December 26, 2007 --
Friday, November 02, 2007 08:00 IST
Gireesh P K, Mumbai
Veeda Clinical Research, one of the leading contract research
organisations (CRO) in the country with presence in Europe and the
US, is set to expand its operations further by acquiring two overseas
companies in the next four months, it is learnt. According to sources
close the development, the company is in the process of finalizing the
acquisitions. In the last two years Veeda has acquired three CROs in
Europe and also set up an office in the US. The planned acquisitions are part of company's global expansion strategy through organic and inorganic ways to conduct clinical trials across geographical locations.
"The company is presently in the midst of both acquisitions", said,
Binoy Gardi, MD, Veeda Clinical Research, UK, in an emailed reply to
Chronicle Pharmabiz. However, he refused to reveal more on the
same.
As per company sources, Veeda is continuing to expand its capabilities
and will be doubling more than the bed space capacity in the next 12
months in India. Currently, the company has a capacity of 116 beds in
four temperature controlled clinical investigation areas in the country.
Veeda, with state-of-the-art phase I facilities in Plymouth in the UK,
Ahmedabad in India and Görlitz in Germany, is planning to invest over
Rs 100 crore to achieve organic and inorganic growth in next 12
months. Earlier this year Veeda has completed the acquisition of DICE,
a CRO based in Belgium. The acquisition of DICE, a highly specialized
CRO with 15 years of experience in data management, biostatistics,
statistical analysis and medical writing for clinical trials, enabled Veeda
to offer the biopharmaceutical market an ever greater depth of
scientific expertise, delivered from sites in the UK, mainland Europe
and the Indian sub continent.
Veeda Clinical Research, which formed as result of amalgamation of
companies in the UK based phase I clinical trials unit and Indian firm
Clinsearch, is a specialist CRO with top class clinical pharmacology
units equipped with a total of 185 beds between both units in
Plymouth, UK and Ahmedabad. Veeda has a dedicated clinical
pathology, bioanalysis, biomarker and immunogenicity laboratory
services which are GLP accredited and has access to an extensive
database of volunteers.
Gireesh P K, Mumbai
Veeda Clinical Research, one of the leading contract research
organisations (CRO) in the country with presence in Europe and the
US, is set to expand its operations further by acquiring two overseas
companies in the next four months, it is learnt. According to sources
close the development, the company is in the process of finalizing the
acquisitions. In the last two years Veeda has acquired three CROs in
Europe and also set up an office in the US. The planned acquisitions are part of company's global expansion strategy through organic and inorganic ways to conduct clinical trials across geographical locations.
"The company is presently in the midst of both acquisitions", said,
Binoy Gardi, MD, Veeda Clinical Research, UK, in an emailed reply to
Chronicle Pharmabiz. However, he refused to reveal more on the
same.
As per company sources, Veeda is continuing to expand its capabilities
and will be doubling more than the bed space capacity in the next 12
months in India. Currently, the company has a capacity of 116 beds in
four temperature controlled clinical investigation areas in the country.
Veeda, with state-of-the-art phase I facilities in Plymouth in the UK,
Ahmedabad in India and Görlitz in Germany, is planning to invest over
Rs 100 crore to achieve organic and inorganic growth in next 12
months. Earlier this year Veeda has completed the acquisition of DICE,
a CRO based in Belgium. The acquisition of DICE, a highly specialized
CRO with 15 years of experience in data management, biostatistics,
statistical analysis and medical writing for clinical trials, enabled Veeda
to offer the biopharmaceutical market an ever greater depth of
scientific expertise, delivered from sites in the UK, mainland Europe
and the Indian sub continent.
Veeda Clinical Research, which formed as result of amalgamation of
companies in the UK based phase I clinical trials unit and Indian firm
Clinsearch, is a specialist CRO with top class clinical pharmacology
units equipped with a total of 185 beds between both units in
Plymouth, UK and Ahmedabad. Veeda has a dedicated clinical
pathology, bioanalysis, biomarker and immunogenicity laboratory
services which are GLP accredited and has access to an extensive
database of volunteers.
Email
Print
SPAM
